NOVARTIS AG ADR-EACH REPR 1 CHF0.5(REGD)

NYSE

NVS

NYSE:NVSearnings and sales also beat estimates and the company raised its guidance for the year. Its Pharmaceuticals business unit grew 10% driven by performance of key drugs like Cosentyx, Entresto and Lutathera while the Sandoz division rose 1% as strong uptake of biosimilars was offset by price erosion in the United States. AVERAGE ANALYSTS PRICE TARGET ...

can someone help me understand..

Novartis RSI is the most oversold it has been in 9 years It now sits on a strong support with a range of just 2 dollars below current levels Fib retracement of 1.618 takes this to 74 dollars before the turnaround All of pharma has taken a hit over the last 4 weeks without real justification. I believe all pop up after they announce earnings throughout the week

this is not an investment advise please do your own research and invest wisely.

NVS Novartis owns or makes a slew of pharmacopial needs for a variety of medical needs. Little dip during recent pullback. Watching Friday ads, all brand names no companies. All Novartis or made for another company by Novartis.

Hay volumen

Glad I am on it.

NVS: novartis ag 2018-06-19 16:02:05 Detected possible FDA approval

I see this going down a bit to $72 but growing after that. Currently a WATCH.

NVS: novartis ag 2018-05-11 18:35:56 Detected possible FDA approval

After touching support around 73$, it's likely to increase 20%

$NVS BULLFLAG WITH TARGETS IN THE 90s

$NVS retrace to .382 and weekly 10 EMA ... reversal today pre market.

NVS plan to CALL due to the break up of down trend line. Consecutive targets are as of each resistant lines.

The price got out of its ranging bound. The lagging span broke the Kijun and had just bounced on the range rectangle before. We may expect the price to lateralize a bit before the earnings and then, if they are positive, to see an uptrend that would make it reach the higher part of the cloud. A retracement after benefits are taken would provide a good entry point...